pembrolizumab

Documents about pembrolizumab

• PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %#982245ClinicalTrials.gov
• Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC#879111ClinicalTrials.gov
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma#471437ClinicalTrials.gov
• Olinvacimab With Pembrolizumab in Patients With mTNBC#847330ClinicalTrials.gov
• KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer#902798ClinicalTrials.gov
• Epacadostat and Pembrolizumab in Patients With GIST#1074353ClinicalTrials.gov
• Pembrolizumab-PET Imaging#1229737ClinicalTrials.gov
• Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer#1339690ClinicalTrials.gov
• Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive#871129ClinicalTrials.gov
• Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma#918108ClinicalTrials.gov
• Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)#1057804ClinicalTrials.gov
• Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer#876089ClinicalTrials.gov
• Pembrolizumab Plus Lenvatinib in Unresectable Cutaneous Angiosarcoma Patients#981850ClinicalTrials.gov
• Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma#1185270ClinicalTrials.gov
• Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients#1337296ClinicalTrials.gov
• IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)#290967ClinicalTrials.gov
• PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients#848577ClinicalTrials.gov
• Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%#1127733ClinicalTrials.gov
• Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma#810182ClinicalTrials.gov
• TATE and Pembrolizumab (MK3475) in mCRC and NSCLC#966140ClinicalTrials.gov
• "QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer#1259635ClinicalTrials.gov
• Palbociclib and Pembrolizumab in Sarcoma#651238ClinicalTrials.gov
• Pembrolizumab in Hepatocellular Carcinoma#1173571ClinicalTrials.gov
• Pembrolizumab Plus Y90 Radioembolization in HCC Subjects#846917ClinicalTrials.gov
• Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)#1114199ClinicalTrials.gov
• Cisplatin+Pembrolizumab+RT in Vulvar Cancer#1173829ClinicalTrials.gov
• Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer#249581ClinicalTrials.gov
• Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients#830170ClinicalTrials.gov
• Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer#845458ClinicalTrials.gov
• Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma#892954ClinicalTrials.gov
• Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)#900221ClinicalTrials.gov
• A Study of Pembrolizumab and Cryoablation in People With Mesothelioma#908127ClinicalTrials.gov
• Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC#1280938ClinicalTrials.gov
• Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC#1378731ClinicalTrials.gov
• Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma#803882ClinicalTrials.gov
• Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma#838825ClinicalTrials.gov
• A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum#914799ClinicalTrials.gov
• Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)#444864ClinicalTrials.gov
• Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors#810484ClinicalTrials.gov
• Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma#833297ClinicalTrials.gov
• Perioperative Chemo and Pembrolizumab in Gastric Cancer#841088ClinicalTrials.gov
• Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)#857700ClinicalTrials.gov
• Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study#1033486ClinicalTrials.gov
• Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer#1112424ClinicalTrials.gov
• Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer#1350847ClinicalTrials.gov
• Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer#917821ClinicalTrials.gov
• Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')#979345ClinicalTrials.gov
• Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab#1126005ClinicalTrials.gov
• CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)#1243978ClinicalTrials.gov
• Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer#1281388ClinicalTrials.gov